Pathology Research

The Department of Pathology financially seeds and supports basic and clinical research programs in pathology. These research programs seek to uncover innovative new approaches, correlate outcomes, and solve the many puzzles of the prevention, diagnosis and treatment of pediatric diseases in an atmosphere that encourages openness with the research community at large.

Featured researchers in the Department of Pathology hold faculty appointments at Harvard Medical School.

Latest Research in Pathology

Roberto Chiarle, MD Genetics and chromosomal translocations in lymphoma and other cancers
Mark Fleming, MD, DPhil Molecular genetics of erythroid iron metabolism
Hannah Kinney, MD SIDS
Maria K. Lehtinen, PhD Cerebrospinal fluid-based signaling in the nervous system
Hanno Steen, PhD Proteomics

Our Current Research and Innovation Efforts

  • Biology and genomics of pediatric gliomas
  • Classification of acute myeloid leukemia (AML) and specifically clinical significance of dysplasia in AML
  • Clinical significance and cytogenetic findings in mixed phenotype acute leukemia (MPAL)
  • Clinicopathologic features of pediatric gastrointestinal diseases including celiac disease and idiopathic inflammatory bowel disease.
  • Clinicopathologic features of sporadic and syndromic polyps of the lumenal gastrointestinal tract.
  • CNS malformations and neurometabolic disorders
  • Correlation of advanced neuroimaging and normal and abnormal CNS histology
  • Developmental brain abnormalities, particularly in premature infants
  • Discovery and pre-clinical validation of novel genetic lesions in lymphoma and solid tumors
  • Ethical issues in medical malpractice expert witness testimony
  • Exosomal microRNA (miRNA, miR) as a biomarker in neuropsychiatric diseases
  • Histologic features in congenital nevi in children under the age of 2 years old.
  • iCAT Study: Multi-institutional collaboration, profiling pediatric solid tumors.
  • Identification and characterization of novel translocations in pediatric cancers.
  • Indicators of clonal progression in pediatric myelodysplastic syndromes and bone marrow failure.
  • Malignant melanoma in the pediatric age group
  • Mechanisms and therapy of ALK driven cancers, including the development of a specific cancer vaccine
  • Mechanisms of pulmonary injury and maldevelopment
  • Mechanisms that govern the formation of chromosomal translocations in normal and neoplastic cells
  • Molecular genetics of inherited anemias, particularly sideroblastic anemias
  • Molecular genetics of iron metabolism disorders
  • Molecular genetics of pediatric bone marrow failure disorders and myelodysplastic syndromes
  • Molecular genetics of pediatric myelodysplastic syndromes and bone marrow failure disorders.
  • Molecular profiling of pediatric solid tumors and hematologic malignancies
  • Myofiber architecture in congenital heart defects
  • Neuropathology of traumatic brain injury, including chronic traumatic enchepalopathy
  • Papillary thyroid carcinoma in children
  • Pathobiology of congenital myopathies and muscular dystrophies
  • Pathobiology of non-rhabdomyosarcomatous soft tissue tumors
  • Pathobiology of pediatric solid tumors
  • Pathobiology of pediatric tumors and tumor-like lesions
  • Pathobiology of rhabdomyosarcoma
  • Pathologic diagnosis of pediatric metabolic/genetic disorders
  • Pathology of pediatric tumors
  • Pediatric renal pathology: Growth and development
  • Pediatric renal pathology: Immune consequences of T-cell dysfunction
  • Pediatric renal pathology: Metabolic abnormalities
  • Pediatric renal pathology: Whole slide imaging and three-dimensional reconstruction
  • Placental pathology associated with untoward outcome in term pregnancies
  • Postmortem imaging as adjunct to or replacement for autopsy
  • Precision medicine diagnostics and clinical trials of brain tumors
  • Profile Study: Molecular profiling of cancers through the Dana Farber Cancer Institute.
  • Spitz nevus and atypical spitzoid melanocytic proliferations.
  • Trials of neuroprotective agents in CNS hypoxic/ischemic injury
  • Vascular malformations and tumors